• Something wrong with this record ?

Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study

A. Linhart, G. Dostálová, K. Nicholls, ML. West, C. Tøndel, A. Jovanovic, P. Giraldo, B. Vujkovac, T. Geberhiwot, E. Brill-Almon, S. Alon, R. Chertkoff, R. Rocco, D. Hughes

. 2023 ; 18 (1) : 332. [pub] 20231021

Language English Country England, Great Britain

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc24001007

BACKGROUND: Pegunigalsidase alfa is a novel, PEGylated α-galactosidase-A enzyme-replacement therapy approved in the EU and US to treat patients with Fabry disease (FD). OBJECTIVE/METHODS: BRIDGE is a phase 3 open-label, switch-over study designed to assess safety and efficacy of 12 months of pegunigalsidase alfa (1 mg/kg every 2 weeks) treatment in adults with FD who had been previously treated with agalsidase alfa (0.2 mg/kg every 2 weeks) for ≥ 2 years. RESULTS: Twenty-seven patients were screened; 22 met eligibility criteria; and 20 (13 men, 7 women) completed the study. Pegunigalsidase alfa was well-tolerated, with 97% of treatment-emergent adverse events (TEAEs) being of mild or moderate severity. The incidence of treatment-related TEAEs was low, with 2 (9%) discontinuations due to TEAEs. Five patients (23%) reported infusion-related reactions. Overall mean (SD; n = 22) baseline estimated glomerular filtration rate (eGFR) was 82.5 (23.4) mL/min/1.73 m2 and plasma lyso-Gb3 level was 38.3 (41.2) nmol/L (men: 49.7 [45.8] nmol/L; women: 13.8 [6.1] nmol/L). Before switching to pegunigalsidase alfa, mean (standard error [SE]) annualized eGFR slope was - 5.90 (1.34) mL/min/1.73 m2/year; 12 months post-switch, the mean eGFR slope was - 1.19 (1.77) mL/min/1.73 m2/year; and mean plasma lyso-Gb3 reduced by 31%. Seven (35%) out of 20 patients were positive for pegunigalsidase alfa antidrug antibodies (ADAs) at ≥ 1 study timepoint, two of whom had pre-existing ADAs at baseline. Mean (SE) changes in eGFR slope for ADA-positive and ADA-negative patients were + 5.47 (3.03) and + 4.29 (3.15) mL/min/1.73 m2/year, respectively, suggesting no negative impact of anti-pegunigalsidase alfa ADAs on eGFR slope. CONCLUSION: Pegunigalsidase alfa may offer a safe and effective treatment option for patients with FD, including those previously treated with agalsidase alfa. TRN: NCT03018730. Date of registration: January 2017.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24001007
003      
CZ-PrNML
005      
20240213093544.0
007      
ta
008      
240109s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s13023-023-02937-6 $2 doi
035    __
$a (PubMed)37865771
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Linhart, Aleš $u 2nd Department of Internal Cardiovascular Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, U Nemocnice 2, 128 08, Prague 2, Czech Republic. ales.linhart@vfn.cz $1 https://orcid.org/0000000233727850 $7 mzk2003188958
245    10
$a Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study / $c A. Linhart, G. Dostálová, K. Nicholls, ML. West, C. Tøndel, A. Jovanovic, P. Giraldo, B. Vujkovac, T. Geberhiwot, E. Brill-Almon, S. Alon, R. Chertkoff, R. Rocco, D. Hughes
520    9_
$a BACKGROUND: Pegunigalsidase alfa is a novel, PEGylated α-galactosidase-A enzyme-replacement therapy approved in the EU and US to treat patients with Fabry disease (FD). OBJECTIVE/METHODS: BRIDGE is a phase 3 open-label, switch-over study designed to assess safety and efficacy of 12 months of pegunigalsidase alfa (1 mg/kg every 2 weeks) treatment in adults with FD who had been previously treated with agalsidase alfa (0.2 mg/kg every 2 weeks) for ≥ 2 years. RESULTS: Twenty-seven patients were screened; 22 met eligibility criteria; and 20 (13 men, 7 women) completed the study. Pegunigalsidase alfa was well-tolerated, with 97% of treatment-emergent adverse events (TEAEs) being of mild or moderate severity. The incidence of treatment-related TEAEs was low, with 2 (9%) discontinuations due to TEAEs. Five patients (23%) reported infusion-related reactions. Overall mean (SD; n = 22) baseline estimated glomerular filtration rate (eGFR) was 82.5 (23.4) mL/min/1.73 m2 and plasma lyso-Gb3 level was 38.3 (41.2) nmol/L (men: 49.7 [45.8] nmol/L; women: 13.8 [6.1] nmol/L). Before switching to pegunigalsidase alfa, mean (standard error [SE]) annualized eGFR slope was - 5.90 (1.34) mL/min/1.73 m2/year; 12 months post-switch, the mean eGFR slope was - 1.19 (1.77) mL/min/1.73 m2/year; and mean plasma lyso-Gb3 reduced by 31%. Seven (35%) out of 20 patients were positive for pegunigalsidase alfa antidrug antibodies (ADAs) at ≥ 1 study timepoint, two of whom had pre-existing ADAs at baseline. Mean (SE) changes in eGFR slope for ADA-positive and ADA-negative patients were + 5.47 (3.03) and + 4.29 (3.15) mL/min/1.73 m2/year, respectively, suggesting no negative impact of anti-pegunigalsidase alfa ADAs on eGFR slope. CONCLUSION: Pegunigalsidase alfa may offer a safe and effective treatment option for patients with FD, including those previously treated with agalsidase alfa. TRN: NCT03018730. Date of registration: January 2017.
650    _2
$a dospělí $7 D000328
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé $7 D006801
650    _2
$a ženské pohlaví $7 D005260
650    12
$a Fabryho nemoc $x farmakoterapie $7 D000795
650    _2
$a alfa-galaktosidasa $x terapeutické užití $7 D000519
650    _2
$a izoenzymy $x škodlivé účinky $7 D007527
650    _2
$a výsledek terapie $7 D016896
650    _2
$a protilátky $x terapeutické užití $7 D000906
650    _2
$a enzymová substituční terapie $x metody $7 D056947
650    _2
$a rekombinantní proteiny $x terapeutické užití $7 D011994
655    _2
$a časopisecké články $7 D016428
700    1_
$a Dostálová, Gabriela $u 2nd Department of Internal Cardiovascular Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, U Nemocnice 2, 128 08, Prague 2, Czech Republic
700    1_
$a Nicholls, Kathy $u Department of Nephrology, Royal Melbourne Hospital and The University of Melbourne, Parkville, Australia
700    1_
$a West, Michael L $u Division of Nephrology, Department of Medicine, Dalhousie University, Halifax, NS, Canada
700    1_
$a Tøndel, Camilla $u Department of Clinical Science, University of Bergen, Bergen, Norway $u Nephrology and Rheumatology Unit, Department of Pediatrics, Haukeland University Hospital, Bergen, Norway
700    1_
$a Jovanovic, Ana $u Department of Inherited Metabolic Disease, Salford Royal, Salford, England, UK
700    1_
$a Giraldo, Pilar $u Centro de Investigación Biomédica en Red de Enfermedades Raras, Hospital de Dia Quiron, Zaragoza, Spain
700    1_
$a Vujkovac, Bojan $u Department of Internal Medicine, General Hospital Slovenj Gradec, Slovenj Gradec, Slovenia
700    1_
$a Geberhiwot, Tarekegn $u Department of Diabetes, Endocrinology and Metabolism, University Hospitals Birmingham NHS Foundation Trust and University of Birmingham, Birmingham, England, UK
700    1_
$a Brill-Almon, Einat $u Protalix Biotherapeutics, Carmiel, Israel
700    1_
$a Alon, Sari $u Protalix Biotherapeutics, Carmiel, Israel
700    1_
$a Chertkoff, Raul $u Protalix Biotherapeutics, Carmiel, Israel
700    1_
$a Rocco, Rossana $u Chiesi Farmaceutici S.p.A., Parma, Italy
700    1_
$a Hughes, Derralynn $u Lysosomal Storage Disorders Unit, Royal Free London NHS Foundation Trust and University College London, London, England, UK
773    0_
$w MED00165365 $t Orphanet journal of rare diseases $x 1750-1172 $g Roč. 18, č. 1 (2023), s. 332
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37865771 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240109 $b ABA008
991    __
$a 20240213093541 $b ABA008
999    __
$a ok $b bmc $g 2049558 $s 1210701
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 18 $c 1 $d 332 $e 20231021 $i 1750-1172 $m Orphanet journal of rare diseases $n Orphanet J Rare Dis $x MED00165365
LZP    __
$a Pubmed-20240109

Find record

Citation metrics

Archiving options